ALERT: This system is being upgraded on Tuesday December 12. It will not be available
for use for several hours that day while the upgrade is in progress. Deposits to DukeSpace
will be disabled on Monday December 11, so no new items are to be added to the repository
while the upgrade is in progress. Everything should be back to normal by the end of
day, December 12.
RAD52 variants predict platinum resistance and prognosis of cervical cancer.
Abstract
RAD52 is an important but not well characterized homologous recombination repair gene
that can bind to single-stranded DNA ends and mediate the DNA-DNA interaction necessary
for the annealing of complementary DNA strands. To evaluate the role of RAD52 variants
in the response of tumor cells to platinum agents, we investigated their associations
with platinum resistance and prognosis in cervical cancer patients. We enrolled 154
patients with cervical squamous cell carcinoma, who had radical surgery between 2008
and 2009, and genotyped three potentially functional RAD52 variants by the SNaPshot
assay. We tested in vitro platinum resistance and RAD52 expression by using the MTT
and immunohistochemistry methods, respectively. In 144 cases who had genotyping data,
we found that both the rs1051669 variant and RAD52 protein expression were significantly
associated with carboplatin resistance (P = 0.024 and 0.028, respectively) and rs10774474
with nedaplatin resistance (P = 0.018). The rs1051669 variant was significantly associated
with RAD52 protein expression (adjusted OR = 4.7, 95% CI = 1.4-16.1, P = 0.013). When
these three RAD52 variants were combined, progression-free survival was lower in patients
who carried at least one (≥1) variant allele compared to those without any of the
variant alleles (P = 0.047). Therefore, both RAD52 variants and protein expression
can predict platinum resistance, and RAD52 variants appeared to predict prognosis
in cervical cancer patients. Large studies are warranted to validate these findings.
Type
Journal articleSubject
HumansOrganoplatinum Compounds
Carboplatin
Immunohistochemistry
Models, Statistical
Drug Resistance, Neoplasm
Genotype
Polymorphism, Single Nucleotide
Adult
Aged
Middle Aged
Uterine Cervical Neoplasms
Female
Rad52 DNA Repair and Recombination Protein
Young Adult
Permalink
https://hdl.handle.net/10161/17990Published Version (Please cite this version)
10.1371/journal.pone.0050461Publication Info
Shi, Ting-Yan; Yang, Gong; Tu, Xiao-Yu; Yang, Jing-Min; Qian, Ji; Wu, Xiao-Hua; ...
Wei, Qingyi (2012). RAD52 variants predict platinum resistance and prognosis of cervical cancer. PloS one, 7(11). pp. e50461. 10.1371/journal.pone.0050461. Retrieved from https://hdl.handle.net/10161/17990.This is constructed from limited available data and may be imprecise. To cite this
article, please review & use the official citation provided by the journal.
Collections
More Info
Show full item recordScholars@Duke
Qingyi Wei
Professor in Population Health Sciences
Qingyi Wei, MD, PhD, Professor in the Department of Medicine, is Associate Director
for Cancer Control and Population Sciences, Co-leader of CCPS and Co-leader of Epidemiology
and Population Genomics (Focus Area 1). He is a professor of Medicine and an internationally
recognized epidemiologist focused on the molecular and genetic epidemiology of head
and neck cancers, lung cancer, and melanoma. His research focuses on biomarkers and
genetic determinants for the DNA repair deficient phenotype and

Articles written by Duke faculty are made available through the campus open access policy. For more information see: Duke Open Access Policy
Rights for Collection: Scholarly Articles
Works are deposited here by their authors, and represent their research and opinions, not that of Duke University. Some materials and descriptions may include offensive content. More info